Alzheimer's Disease
Topline results: Donanemab superior to aducanumab in early symptomatic Alzheimer’s disease
BOSTON — More patients with early symptomatic Alzheimer’s disease reached amyloid clearance and plaque reductions at 6 months with donanemab vs. aducanumab, according to a presentation at the American Academy of Neurology annual meeting.
FDA advisory committees rule in favor of Rexulti for agitation associated with Alzheimer’s
Two FDA advisory committees voted in favor of a supplemental new drug application for Rexulti, ruling there was sufficient data to show treatment for agitation associated with Alzheimer’s dementia outweighed the risks.
Vascular dementia, Alzheimer’s disease influence outcomes for people with AF
Adults with atrial fibrillation and vascular dementia have a higher risk for stroke, rehospitalization and mortality compared with those with AF and Alzheimer’s disease, who have a higher risk for intercranial hemorrhage, data show.
Walgreens, Prothena partner to boost enrollment for Alzheimer’s disease clinical trial
Walgreens and Prothena have announced a partnership to expand patient identification and recruitment for Prothena’s ongoing study of PRX012, an investigational anti-amyloid beta antibody for the treatment of Alzheimer’s disease.
Omega-3 fatty acids might reduce cognitive decline risk
Omega-3 fatty acid may reduce the risk for cognitive decline and could be particularly helpful for populations at high genetic risk for Alzheimer’s disease, according to researchers.
Top in women’s health: Alzheimer’s disease vulnerability; ozone exposure during pregnancy
Developing menopause at an earlier age and late initiation of hormone therapy were associated with increased vulnerability to Alzheimer’s disease, according to researchers.
Modified Mediterranean ketogenic diet may improve brain health
A modified Mediterranean ketogenic diet was associated with changes in a biological pathway linked to Alzheimer’s disease among older adults with mild cognitive impairment, according to study results published in Alzheimer’s and Dementia.
Family of Estée Lauder donates $200M to Alzheimer’s research
The descendants of Estée Lauder donated $200 million to the Alzheimer’s Drug Discovery Foundation to help prevent, diagnose, treat and cure the disease, according to a press release.
Biogen’s investigational therapy reduced tau protein levels in patients with Alzheimer’s
Biogen Inc. has reported promising data from a phase 1b trial of BIIB080, an investigational antisense oligonucleotide therapy that reduced soluble tau protein in cerebrospinal fluid in patients with early Alzheimer’s disease.
Earlier age at menopause, later HT initiation linked to Alzheimer’s disease vulnerability
Being younger at menopause onset and initiating hormone therapy after more than 5 years were both linked to increased tau vulnerability among women, according to a cross-sectional study published in JAMA Neurology.